Anju Karki
YOU?
Author Swipe
View article: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of <i>KRAS</i> -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of <i>KRAS</i> -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial Open
PURPOSE This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab for the second-line treatment o…
View article: Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas Open
Occurrence of resistance to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) approved in ovarian carcinoma, has already been shown in clinical settings. Identifying combination treatments to sensitize tumor cells and/or ove…
View article: Data from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Data from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Polo-like kinase 1 (Plk1) plays an important role in cell-cycle regulation. Recent work has suggested that Plk1 could be a biomarker of gemcitabine response in pancreatic ductal adenocarcinoma (PDAC). Although targeting Plk1 to treat PDAC …
View article: Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Supplementary Figure from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Figure from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Figure from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Data from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Data from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Polo-like kinase 1 (Plk1) plays an important role in cell-cycle regulation. Recent work has suggested that Plk1 could be a biomarker of gemcitabine response in pancreatic ductal adenocarcinoma (PDAC). Although targeting Plk1 to treat PDAC …
View article: Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Supplementary Figure from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Supplementary Figure from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Supplementary Figure from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
View article: Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy Open
Polo-like kinase 1 (Plk1) plays an important role in cell-cycle regulation. Recent work has suggested that Plk1 could be a biomarker of gemcitabine response in pancreatic ductal adenocarcinoma (PDAC). Although targeting Plk1 to treat PDAC …
View article: Plexin-B2 and Semaphorins Do Not Drive Rhabdomyosarcoma Proliferation or Migration
Plexin-B2 and Semaphorins Do Not Drive Rhabdomyosarcoma Proliferation or Migration Open
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma for which subsets of patients have longstanding unmet clinical needs. For example, children with alveolar rhabdomyosarcoma and metastases at diagnosis will experience …
View article: DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling
DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling Open
Fibrolamellar carcinoma (FLC) is a primary liver cancer that most commonly arises in adolescents and young adults in a background of normal liver tissue and has a poor prognosis due to lack of effective chemotherapeutic agents. The DNAJB1-…
View article: <i>DNAJB1-PRKACA</i> in HEK293T cells induces <i>LINC00473</i> overexpression that depends on PKA signaling
<i>DNAJB1-PRKACA</i> in HEK293T cells induces <i>LINC00473</i> overexpression that depends on PKA signaling Open
Fibrolamellar carcinoma (FLC) is a primary liver cancer that most commonly arises in adolescents and young adults in a background of normal liver tissue and has an poor prognosis due to lack of effective chemotherapeutic agents. The DNAJB1…
View article: Receptor-driven invasion profiles in diffuse intrinsic pontine glioma
Receptor-driven invasion profiles in diffuse intrinsic pontine glioma Open
Background Diffuse intrinsic pontine glioma (DIPG) is a devastating pediatric cancer with unmet clinical need. DIPG is invasive in nature, where tumor cells interweave into the fiber nerve tracts of the pons making the tumor unresectable. …
View article: Additional file 1 of Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Additional file 1 of Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma Open
Additional file 3: Table 1. Table of information, properties, and clinical and genomic characteristics for cell lines used in this study.
View article: MDM4 expression in fibrolamellar hepatocellular carcinoma
MDM4 expression in fibrolamellar hepatocellular carcinoma Open
Fibrolamellar hepatocellular carcinoma (FL‑HCC) is a variant of hepatocellular carcinoma (HCC) that most commonly affects adolescents and young adults and is associated with an extremely poor prognosis due to the lack of effective chemothe…
View article: A single transcription factor is sufficient to induce and maintain secretory cell architecture
A single transcription factor is sufficient to induce and maintain secretory cell architecture Open
We hypothesized that basic helix–loop–helix (bHLH) MIST1 (BHLHA15) is a “scaling factor” that universally establishes secretory morphology in cells that perform regulated secretion. Here, we show that targeted deletion of MIST1 caused dism…
View article: MIST1 Links Secretion and Stress as both Target and Regulator of the Unfolded Protein Response
MIST1 Links Secretion and Stress as both Target and Regulator of the Unfolded Protein Response Open
Transcriptional networks that govern secretory cell specialization, including instructing cells to develop a unique cytoarchitecture, amass extensive protein synthesis machinery, and be embodied to respond to endoplasmic reticulum (ER) str…
View article: Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice
Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice Open
Liposarcomas (LPSs) are the most common soft-tissue cancer. Because of the lack of animal models, the cellular origin and molecular regulation of LPS remain unclear. Here, we report that mice with adipocyte-specific activation of Notch sig…
View article: Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer Open
Gemcitabine is the standard-of-care for chemotherapy in patients with pancreatic adenocarcinoma and it can directly incorporate into DNA or inhibit ribonucleotide reductase to prevent DNA replication and, thus, tumor cell growth. Most panc…
View article: Investigating the role of the basic helix-loop-helix transcription factor MIST1 in pancreatic diseases
Investigating the role of the basic helix-loop-helix transcription factor MIST1 in pancreatic diseases Open
Acinar cells of the exocrine pancreas are dedicated to synthesize, package and secrete immense quantities of pro-digestive enzymes to maintain proper metabolic homeostasis for the organism. Dysregulation of enzyme secretion in acinar cells…